GE's US $1.06 billion acquisition of Thermo Fisher Scientific's gene regulation and magnetic bead business

Source: Financial Times 2014-1-7 General Electric has agreed to buy gene regulation and bead business from Thermo Fisher Scientific for us $1.06 billion The deal will strengthen GE's Life Sciences Division The new business will be integrated into GE Healthcare and enter GE's technology development and drug, vaccine and diagnostic product platforms Ge decided to enter the market for high-tech and high margin deals, which also helped its ambitious goals John Dineen, chief executive of GE Healthcare, said life sciences is one of GE's strongest and fastest growing sectors driven by global demand for improved diagnosis and treatment and new, safer drugs The integration of GE's engineering expertise and life science capabilities has benefited the industry, R & D and patients The deal will add to the picture and help more people enjoy better services with the least money In addition to its gene regulation and bead business, GM also acquired cell culture from Thermo Fisher The combined revenue of the three sectors last year was $250 million